In late 2001, federal regulators refused to accept Imclone's (nasdaq: IMCL - news - people ) application for Erbitux, questioning its clinicaltrial data.
Boston Scientific released positive clinicaltrial results last month and is in the process of preparing to submit application for approval for its device in Europe.